Demonstration of GAD-65 As the Main Immunogenic Isoform of Glutamate Decarboxylase in Type 1 Diabetes and Determination of Autoantibodies Using a Radioligand Produced by Eukaryotic Expression
Overview
Affiliations
Plasmids containing cDNA for the rat 67- and 65-kD isoforms of glutamate decarboxylase (GAD-67 and GAD-65) were expressed in COS-cells, and lysates of [35S]methionine-labeled cells were used for immunoprecipitations. Sera from 38 patients with type 1 (insulin-dependent) diabetes mellitus, which precipitated a 64-kD antigen from rat islets, reacted with recombinant GAD-65 in relation to their anti-64-kD titers. The eight strongest sera also precipitated recombinant GAD-67, suggesting that certain epitopes are common to both isoforms. Subsequently, [35S]methionine-labeled GAD-65 was purified from COS cell lysates and employed in a binding assay with 50 sera of patients with recent onset of type 1 diabetes mellitus. 38 sera (76%) precipitated labeled GAD-65 with titers that correlated with islet cell antibodies (ICA), determined in a standard immunofluorescence assay. 2 sera were GAD positive but ICA negative, 4 were positive only for ICA, and 6 were negative for both GAD and ICA, as were the sera of 20 controls. The data illustrate that antibodies against GAD-65 are present in a majority of patients with type 1 diabetes mellitus and that autoantibodies against other islet cell antigens also exist. The radioligand-binding assay, which is convenient and sensitive for detecting GAD antibodies, will facilitate the screening of individuals with autoimmune islet cell disease.
Liu X, Zheng Y, Guasch-Ferre M, Ruiz-Canela M, Toledo E, Clish C Nutr Metab Cardiovasc Dis. 2019; 29(10):1040-1049.
PMID: 31377179 PMC: 9257877. DOI: 10.1016/j.numecd.2019.06.005.
Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus.
Doran T, Morimoto J, Simanski S, Koesema E, Clark L, Pels K Cell Chem Biol. 2016; 23(5):618-628.
PMID: 27185639 PMC: 4890052. DOI: 10.1016/j.chembiol.2016.04.006.
Discovery of native autoantigens via antigen surrogate technology: application to type 1 diabetes.
Doran T, Simanski S, Kodadek T ACS Chem Biol. 2014; 10(2):401-12.
PMID: 25474415 PMC: 4339956. DOI: 10.1021/cb5007618.
Clinical potential of antigen-specific therapies in type 1 diabetes.
Coppieters K, Sehested Hansen B, von Herrath M Rev Diabet Stud. 2013; 9(4):328-37.
PMID: 23804270 PMC: 3740700. DOI: 10.1900/RDS.2012.9.328.
Trials in type 1 diabetes: Antigen-specific therapies.
Coppieters K, Harrison L, von Herrath M Clin Immunol. 2013; 149(3):345-55.
PMID: 23490422 PMC: 5777514. DOI: 10.1016/j.clim.2013.02.002.